FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Tarceva